<DOC>
	<DOCNO>NCT00710125</DOCNO>
	<brief_summary>This Phase 1 safety dose escalation study define maximum tolerate dose ( MTD ) identify dose limit toxicity ( DLT ) follow IV administration GPX-150 every 3 week . Escalating dos start dose 14 mg/m2 increase dose 265 mg/m2 administer IV every 3 week 8 cycle treatment . Patients previously receive anthracycline limit 4 cycle treatment .</brief_summary>
	<brief_title>Safety Study GPX-150 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patient least 18 year age . Patient histologically cytologically confirm diagnosis solid tumor . Patient progressive disease Patient consider incurable disease candidate know effective systemic treatment . Patient performance status least 70 % Karnofsky scale . Patient receive cytotoxic chemotherapy investigational agent within 4 week first treatment study ( 6 week mitomycin nitrosourea ) . Patients receive supportive care indicate . Patients currently receive blood transfusion erythropoiesisstimulating agent continue receive per ASCO guideline . Patients require palliative radiation therapy complete course radiation treatment 4 week first study treatment . Patient may receive unlimited prior hormonal therapy , must complete least 4 week prior first study treatment , progressive disease document follow withdrawal hormone therapy . Patient hormonerefractory prostate cancer long act LHRH agent may continue agent . Patient may receive unlimited prior biological immunological therapy without limitation , must complete least 4 week prior first study treatment . Patient fully recover previous surgery ( least 4 week since major surgery ) radiation therapy ( least 4 week since end treatment ) . Patient recover reversible toxicity prior therapy . Permanent stable side effect change acceptable ≤ Grade 2 . Patient adequate hematological function define ANC ≥ 1500 , platelets ≥ 100,000/µL , hemoglobin ≥9.0 gm/dL . Patient adequate organ function define bilirubin ≤ 1.5 time ULN , AST ALT &lt; 2.5 time upper limit normal ( ULN , 5.0 time ULN liver involvement ) , serum creatinine &lt; 2.0 dL estimate creatinine clearance ≥ 50 ml/min . Patient ejection fraction 110 % low limit institutional normal determine rest MUGA scan . Patient O2 Sat pulse oximetry least 90 % . Patient negative pregnancy test prior study entry premenopausal le 12 month menopause . Premenopausal patient must use medically effective form contraception treatment period . Patient willing able comply study protocol requirement . The patient legally authorize representative must fully understand element informed consent sign informed consent accord institutional federal regulatory requirement . Patient pregnant breastfeeding . Patient history hypersensitivity anthracyclines . Patient receive cumulative dose doxorubicin exceed 300 mg/m2 cumulative dose epirubicin exceed 540 mg/m2 . Patient receive anthracycline within 6 month prior entry study . Patient brain metastasis unless asymptomatic stable glucocorticoid . Prior history CHF , myocardial infarction within 6 month prior enrollment , active ischemic heart disease , uncontrolled hypertension . Patient require active medical therapy CHF arrhythmia . Patients &gt; Grade l motor neuropathy &gt; Grade 2 sensory neuropathy . Patient participate study investigational drug within 4 week prior first study treatment . Patient receive chemotherapy , hormonal therapy ( exception LHRH prostate cancer ) , immunotherapy , biological therapy , radiotherapy within 4 week prior first study treatment . Patient major surgery within 4 week first study treatment . Patient receive GCSF GMCSF within 4 week prior first dose study drug . Patient baseline laboratory value outside normal range list ( see Inclusion Criteria ) , clinically significant determine investigator . Patient serious , concurrent medical condition would limit patient 's ability complete comply study requirement . Patient unable unwilling comply contraceptive requirement study period . Patient lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>